MELBOURNE, Australia and INDIANAPOLIS, Jan. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

(RTTNews) - Stifel Financial Corp. (SF) revealed earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $234.69 million ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

Stifel noted that Reuters reported this morning that Japan’s NEC is considering making a bid for CSG Systems (CSGS) and that talks between the two are in “early stages.” NEC owns Netcracker ...

Stifel Financial (SF) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to earnings of $1.50 per share a year ago.

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Olympic silver medalist Jaelin Kauf earned her first World Cup moguls victory in more than six years while extending her ...

On Monday, Stifel analysts maintained a Buy rating on ServiceTitan stock (NASDAQ:TTAN) with a steady price target of $120.00. The company, currently trading at $92.56 with a market capitalization ...

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp., according to people familiar with the matter. The partnership at ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...